AAFA Comments on New Model for School Health Services in DC
AAFA provided comments expressing concern over the new model for school health services that will be implemented in DC public schools and public charter schools starting in January 2017.
AAFA Letter About the Rising Costs of Epinephrine Auto-Injectors
AAFA’s CEO addresses issues of access and affordability of life-saving epinephrine auto-injectors.
Air Travel and Disabilites
AAFA commented to the Department of Transportation explaining why asthma and allergies should be taken into consideration as disabilities during airline travel.
Anaphylaxis Protocols in Federal Facilities
AAFA sent a letter to Federal Occupational Health (FOH) in support of epinephrine stocking and improved allergy policies in federal facilities.
South Carolina's Emergency Anaphylaxis Treatment Act
AAFA sent a letter in support of South Carolina’s Emergency Anaphylaxis Treatment Act, which would expand access to epinephrine in public places.
Food Labeling Modernization Act
AAFA sent a letter to the sponsors of the Food Labeling Modernization Act of 2015 to thank them for introducing the legislation.
FDA Allergenic Products Advisory Committee
AAFA CEO Cary Sennett represented allergy patients’ perspective in testimony before the FDA’s Allergenic Products Advisory Committee.
Institute of Medicine Food Allergy Study
AAFA commented to the Institute of Medicine regarding the study Food Allergies: Global Burden, Causes, Treatment, Prevention, and Public Policy.
To view more position statements and comment letter from AAFA, please click here